PHASE-II EVALUATION OF RECOMBINANT INTERFERON-BETA (IFN-BETA-SER) IN PATIENTS WITH DIFFUSE MESOTHELIOMA - A SOUTHWEST ONCOLOGY GROUP-STUDY

被引：30

作者：

VONHOFF, DD

METCH, B

LUCAS, JG

BALCERZAK, SP

GRUNBERG, SM

RIVKIN, SE

机构：

[1] SW ONCOL GRP 8526,CTR STAT,OPERAT OFF,5430 FREDERICKSBURG RD,SUITE 618,SAN ANTONIO,TX 78229

[2] UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284

[3] OHIO STATE UNIV,CTR HLTH,COLUMBUS,OH 43210

[4] UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033

[5] PUDGET SOUND ONCOL CONSORTIUM,SEATTLE,WA

来源：

JOURNAL OF INTERFERON RESEARCH | 1990年 / 10卷 / 05期

关键词：

D O I：

10.1089/jir.1990.10.531

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Fourteen evaluable patients with diffuse malignant mesothelioma were treated with a once-a-day for 5 days out of 7 for 6 weeks regimen of recombinant interferon-β (IFN-βser). No responses were noted. The major toxicities included fever, chills, nausea, vomiting, and anorexia. IFN-βser at this dose and schedule does not appear to be an active single agent for patients with refractory malignant mesothelioma. © 1990, Mary Ann Liebert, Inc. All rights reserved.

引用

页码：531 / 534

页数：4

共 17 条

[11]

KELSEN DP, 1985, P AN M AM SOC CLIN, V4, P146

[12] PLEURAL MESOTHELIOMA - CLINICAL FEATURES AND THERAPEUTIC IMPLICATIONS [J].